Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

HyperSpectral Imaging in Low Grade Glioma

NCT: NCT04859725 · ACTIVE_NOT_RECRUITING

NCT IDNCT04859725
StatusACTIVE_NOT_RECRUITING
Start Date2021-05-31
Completion2026-06-30

Brief Summary

Low grade glioma (LGG) is a slowly evolving, highly invasive intrinsic brain tumor displaying only subtle tissue differences with the normal surrounding brain, hampering the attempts to visually discriminate tumor from normal brain, especially at the border interface. This makes anatomical borders hard to define during early maximal resection, which is the initial treatment strategy. Therefore, innovative, robust and easy-to-use real-time strategies for intra-operative detection and discrimination of (residual) LGG tumor tissue would strongly influence on-site, surgical decision making, enabling a maximal extent of resection. To validate this approach hyperspectral imaging (HSI) - using a SnapScan HSI-Camera (IMEC), stably mounted on an OPMI Pentero 900 microscope (Zeiss) - will be used to generate spectral imaging data patterns that discriminate in vivo low grade glioma tissue from normal brain both on the cortical and subcortical level.

Frequently Asked Questions

What is HyperSpectral Imaging in Low Grade Glioma?

HyperSpectral Imaging in Low Grade Glioma is a clinical trial registered under NCT04859725. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04859725?

The current status of NCT04859725 (HyperSpectral Imaging in Low Grade Glioma) is: ACTIVE_NOT_RECRUITING.

When did HyperSpectral Imaging in Low Grade Glioma start?

HyperSpectral Imaging in Low Grade Glioma started on 2021-05-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.